--- title: "Best Pharmaceutical Stocks To Watch Today - August 21st" type: "News" locale: "en" url: "https://longbridge.com/en/news/296642984.md" description: "MarketBeat identifies seven pharmaceutical stocks to watch on August 21st based on high trading volume: Eli Lilly, Merck & Co., Johnson & Johnson, AbbVie, Pfizer, Abbott Laboratories, and Jupiter Neurosciences. These companies are highlighted for their significant market activity and potential growth in drug approvals and sales, though they face risks from clinical trials and regulatory decisions." datetime: "2026-08-21T18:02:04.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296642984.md) - [en](https://longbridge.com/en/news/296642984.md) - [zh-HK](https://longbridge.com/zh-HK/news/296642984.md) generator: "portal-rs" --- # Best Pharmaceutical Stocks To Watch Today - August 21st - 2 Biotech Stocks Shaping Up for Major Breakouts Eli Lilly and Company, Merck & Co., Inc., Johnson & Johnson, AbbVie, Pfizer, Abbott Laboratories, and Jupiter Neurosciences are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies involved in discovering, developing, manufacturing, or selling prescription and over-the-counter medicines. For investors, these stocks may offer growth potential from successful drug approvals and strong sales, but they also carry risks related to clinical trials, regulatory decisions, patents, competition, and pricing pressures. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days. Get **Eli Lilly and Company** alerts: ## Eli Lilly and Company (LLY) Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. - The FTC Is Suing Hims & Hers Health—Here's Why Investors Shouldn't Panic Read Our Latest Research Report on LLY ## Merck & Co., Inc. (MRK) Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. - As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner Read Our Latest Research Report on MRK ## Johnson & Johnson (JNJ) Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. Read Our Latest Research Report on JNJ ## AbbVie (ABBV) AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. Read Our Latest Research Report on ABBV ## Pfizer (PFE) Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. Read Our Latest Research Report on PFE ## Abbott Laboratories (ABT) Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. Read Our Latest Research Report on ABT ## Jupiter Neurosciences (JUNS) Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. Read Our Latest Research Report on JUNS ## Further Reading - MarketBeat's Top Five Stocks to Own in August 2026 - Blueprint for a Boom: SEC Clears the Crypto Runway - Ross Stores Just Flipped the Off-Price Retail Story After TJX's Marmaxx Miss - Advance Auto Parts Plunged, But Its Turnaround Is Still Working - Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates? - Meta Platform's Legal Issues Could Become Much More Than A Q2 Earnings Headache *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Eli Lilly and Company Right Now? Before you consider Eli Lilly and Company, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list. While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) - [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md) - [JUNS.US](https://longbridge.com/en/quote/JUNS.US.md) - [MRK.US](https://longbridge.com/en/quote/MRK.US.md) - [PFE.US](https://longbridge.com/en/quote/PFE.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [ABT.US](https://longbridge.com/en/quote/ABT.US.md) - [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md) - [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md) - [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md) - [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md) - [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md) ## Related News & Research - [Why Is Omniab Stock Rallying After Eli Lilly Deal?](https://longbridge.com/en/news/296113651.md) - [Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient](https://longbridge.com/en/news/296005917.md) - [Huge Unusual Put Options Volume in Merck - Is MRK Stock Overvalued?](https://longbridge.com/en/news/296385371.md) - [How Eli Lilly’s Global Vault CRM Rollout At Veeva Systems (VEEV) Has Changed Its Investment Story](https://longbridge.com/en/news/296430987.md) - [TCW Group Inc. Trims Stake in Pfizer Inc. $PFE](https://longbridge.com/en/news/296204181.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**